CRISPR-Cas9 is a widely-used genome editing tool, but its off-target effect and on-target complex mutations remain a concern, especially in view of future clinical applications. Non-human primates (NHPs) share close genetic and physiological similarities with humans, making them an ideal preclinical model for developing Cas9-based therapies. However, to our knowledge no comprehensive in vivo off-target and on-target assessment has been conducted in NHPs. Here, we perform whole genome trio sequencing of Cas9-treated rhesus monkeys. We only find a small number of de novo mutations that can be explained by expected spontaneous mutations, and no unexpected off-target mutations (OTMs) were detected. Furthermore, the long-read sequencing data does not detect large structural variants in the target region.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892871 | PMC |
| http://dx.doi.org/10.1038/s41467-019-13481-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies.
Biomedicines
December 2024
Department of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
Background: Anaplastic lymphoma kinase (ALK) plays a role in the development of lymphoma, lung cancer and neuroblastoma. While tyrosine kinase inhibitors (TKIs) have improved treatment outcomes, relapse remains a challenge due to on-target mutations and off-target resistance mechanisms. ALK-positive (ALK+) tumors can evade the immune system, partly through tumor-associated macrophages (TAMs) that facilitate immune escape.
View Article and Find Full Text PDFT cell receptor (TCR) mimics offer a promising platform for tumor-specific targeting of peptide-MHC in cancer immunotherapy. Here, we designed a α-helical TCR mimic (TCRm) specific for the NY-ESO-1 peptide presented by HLA-A 02, achieving high on-target specificity with nanomolar affinity (K = 9.5 nM).
View Article and Find Full Text PDFPeptide-based CAR-NK cells: A novel strategy for the treatment of solid tumors.
Biochem Pharmacol
January 2025
CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China. Electronic address:
CAR-T cell therapy has been proven to be effective on hematological tumors, although graft-versus-host disease and cytokine release syndrome(CRS) limit its application to a certain extent. However, CAR-T therapy for solid tumors met challenges, among which the lack of tumor-specific antigens (TSA) and immunosuppressive tumor microenvironment (TME) are the most important factors. CAR-NK could be a good alternative to CAR-T in some ways since they can induce mild CRS and are independent of HLA-matching, but the efficacy of CAR-NKs remains limited in solid tumors.
View Article and Find Full Text PDFPredicting CRISPR-Cas9 off-target effects in human primary cells using bidirectional LSTM with BERT embedding.
Bioinform Adv
December 2024
Digital Technologies Research Center, National Research Council Canada, Ottawa, ON, K1A 0R6, Canada.
Motivation: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 system is a ground-breaking genome editing tool, which has revolutionized cell and gene therapies. One of the essential components involved in this system that ensures its success is the design of an optimal single-guide RNA (sgRNA) with high on-target cleavage efficiency and low off-target effects. This is challenging as many conditions need to be considered, and empirically testing every design is time-consuming and costly.
View Article and Find Full Text PDFAn acquired CCDC6:: gene fusion as resistance mechanism for Osimertinib in exon 21 -mutated non-small cell lung cancer and its successful management with Osimertinib and Selpercatinib: a case report and review of literature.
J Chemother
January 2025
Department of Pulmonary Diseases, AZ Delta, Roeselare, Belgium.
Article Synopsis
- EGFR-TKIs are the first-line treatment for patients with advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC), showing better outcomes than chemotherapy, but resistance to these drugs is common.
- In cases of disease progression, rebiopsying patients can help identify resistance mechanisms, which are crucial for developing new treatments.
- A case study of a 78-year-old woman with acquired RET Gene Fusion resistance demonstrated that combining Osimertinib and Selpercatinib was effective, resulting in 14 months of progression-free survival without adverse effects, highlighting the need for further research on such combinations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!